REG - Feedback PLC - Result of AGM

FeedbackAnnouncement

13/10/2025 16:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251013:nRSM1620Da&default-theme=true

RNS Number : 1620D  Feedback PLC  13 October 2025

 

Feedback plc

 

Result of Annual General Meeting

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical
infrastructure specialist, announces that at the Annual General Meeting held
today all resolutions were duly passed.

 

The results of the poll (including proxy votes on the resolutions) are
included below.

 

 Resolutions                                                                     Votes for*  % of votes cast**  Votes against  % of votes cast**  Votes withheld***
 1)   To receive the Annual Report and Accounts for the financial year ended     17,771,063  99.999%            120            0.001%             86
 31 May 2025
 2) To accept the Directors' Remuneration Report for the financial year ended    17,763,723  99.96%             7,386          0.04%              160
 31 May 2025
 3) To re-elect Adam Denning as a director of the Company                        17,756,812  99.97%             6,120          0.03%              8,337
 4) To re-elect Annemijn Eschauzier as a director of the Company                 17,756,546  99.96%             6,386          0.04%              8,337
 5) To re-elect Dr. Tom Oakley as a director of the Company                      17,763,989  99.96%             7,120          0.04%              160
 6) To re-elect Anesh Patel as a director of the Company                         17,764,989  99.97%             6,120          0.03%              160
 7) To re-elect Philipp Prince as a director of the Company                      17,758,796  99.98%             4,136          0.02%              8,337
 8) To re-elect Professor Rory Shaw as a director of the Company                 17,719,573  99.71%             51,536         0.29%              160
 9) To re-appoint Price Bailey LLP as auditor of the Company                     17,770,989  99.999%            120            0.001%             160
 10) To authorise the Directors to determine the fees payable to the auditor     17,770,989  99.999%            120            0.001%             160
 11) To authorise the Directors to allot Equity Securities within the            17,720,805  99.72%             50,304         0.28%              160
 parameters set out in the Notice

 Special Resolutions
 12) Subject to the passing of resolution 11, to authorise the Directors to      17,706,894  99.68%             56,038         0.32%              8,337
 allot Equity Securities for cash as if Section 561 of the CA 2006 did not
 apply
 13) Subject to the passing of resolution 11 and in addition to resolution 12,   17,707,894  99.69%             55,038         0.31%              8,337
 to authorise the Directors to allot Equity Securities for cash as if Section
 561 of the CA 2006 did not apply

 

Notes:

* "Votes For" include votes giving the Chairman discretion.

** Percentages exclude "Votes Withheld".

*** "Votes Withheld" are not votes in law and do not count in the number of
votes counted for or against a resolution.

 

As at 13 October, there were 43,814,779 ordinary shares in issue. Shareholders
are entitled to one vote per share.

 

The full text of each resolution is available in the Notice of Annual General
Meeting, published on the Company's website.

 

-Ends-

 

Enquiries:

 

 Feedback plc                                 +44 (0) 20 3997 7634

 Tom Oakley, CEO                              IR@fbk.com (mailto:IR@fbk.com)

 Anesh Patel, CFO

 Panmure Liberum Limited (NOMAD and Broker)   +44 (0)20 7886 2500

 Emma Earl/ Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Walbrook PR Ltd;                             Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                              (mailto:feedbackplc@walbrookpr.com)
 Nick Rome/Joe Walker                         07748 325 236 or 07407 020 470

 

About Feedback plc

 

Feedback plc liberates the data and knowledge from multiple healthcare IT
systems and delivers better workflow to enable clinicians to communicate,
collaborate and provide the best healthcare for their patients. We connect
care settings with diagnostic and other relevant data to drive better, faster,
safer decision that improve outcomes for patients.

 

By linking different clinical systems together into a seamless view of the
patient, we can streamline patient pathways and deliver a digital health and
diagnostics record across multiple care providers.

 

Bleepa® is our communication and collaboration platform that displays
clinical results at a certified and regulated quality, which enables
multi-disciplinary team working and diagnostic-enhanced advice and guidance.
CareLocker® is our patient-facing platform that gives patients access and
control over their diagnostic and other clinical data.

 

The Company has a number of growth opportunities domestically and
internationally across a range of public and private healthcare markets
including the NHS. Our highly scalable software-as-a-service (SaaS) based
model is expected to provide increasing levels of revenue visibility as the
Company grows its customer base.

 

https://feedbackmedical.com/
(https://urldefense.proofpoint.com/v2/url?u=https-3A__feedbackmedical.com_&d=DwMGaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=lwwmT1lSfgELFLcwvlJQ2ZXDKcVbkQyitKwD17cChBQ&m=oBFM-ht-5vvdSXufzCuQmLfPWIaMcFGcjFY8Tl7Z-dsq0iW8FbXgExGw9gLP3va-&s=kayb21_5OhwDnHa1pJnJQjB1999VQgQynAFl7rWXro4&e=)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGEXLFFEBLBFBF



            Copyright 2019 Regulatory News Service, all rights reserved